CN112402365B - PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating intervertebral disc degeneration diseases - Google Patents
PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating intervertebral disc degeneration diseases Download PDFInfo
- Publication number
- CN112402365B CN112402365B CN202011217356.2A CN202011217356A CN112402365B CN 112402365 B CN112402365 B CN 112402365B CN 202011217356 A CN202011217356 A CN 202011217356A CN 112402365 B CN112402365 B CN 112402365B
- Authority
- CN
- China
- Prior art keywords
- umbilical cord
- cells
- mesenchymal stem
- cord mesenchymal
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000003954 umbilical cord Anatomy 0.000 title claims abstract description 52
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 49
- 239000000203 mixture Substances 0.000 title claims abstract description 44
- 206010061246 Intervertebral disc degeneration Diseases 0.000 title claims abstract description 37
- 208000018180 degenerative disc disease Diseases 0.000 title claims abstract description 26
- 208000021600 intervertebral disc degenerative disease Diseases 0.000 title claims abstract description 26
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 19
- 210000004027 cell Anatomy 0.000 claims abstract description 49
- 108090000190 Thrombin Proteins 0.000 claims abstract description 12
- 229960004072 thrombin Drugs 0.000 claims abstract description 12
- 230000000694 effects Effects 0.000 claims abstract description 11
- 238000002360 preparation method Methods 0.000 claims abstract description 6
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 32
- 239000006228 supernatant Substances 0.000 claims description 20
- 210000000130 stem cell Anatomy 0.000 claims description 18
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 16
- 239000001569 carbon dioxide Substances 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 10
- 230000004927 fusion Effects 0.000 claims description 9
- 238000010009 beating Methods 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 238000007664 blowing Methods 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 239000008354 sodium chloride injection Substances 0.000 claims description 8
- 238000012546 transfer Methods 0.000 claims description 8
- 238000005406 washing Methods 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 5
- 230000001464 adherent effect Effects 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 239000006285 cell suspension Substances 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 4
- 210000003743 erythrocyte Anatomy 0.000 claims description 4
- 230000003203 everyday effect Effects 0.000 claims description 4
- 238000011010 flushing procedure Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000005070 sampling Methods 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 238000000034 method Methods 0.000 abstract description 7
- 230000001172 regenerating effect Effects 0.000 abstract description 4
- 238000011065 in-situ storage Methods 0.000 abstract description 3
- 208000014674 injury Diseases 0.000 abstract description 3
- 230000008569 process Effects 0.000 abstract description 3
- 230000008733 trauma Effects 0.000 abstract description 2
- 208000008930 Low Back Pain Diseases 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 208000008035 Back Pain Diseases 0.000 description 4
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 238000002659 cell therapy Methods 0.000 description 4
- 230000007850 degeneration Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- 101100328886 Caenorhabditis elegans col-2 gene Proteins 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 101100096242 Mus musculus Sox9 gene Proteins 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000008289 pathophysiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0668—Mesenchymal stem cells from other natural sources
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Botany (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention discloses a PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating intervertebral disc degeneration diseases, and particularly relates to the technical field of intervertebral disc degeneration diseases, wherein each 2mL of the composition at least comprises 5X 10-5 umbilical cord mesenchymal stem cells, PRP gel and 100 units of thrombin, and as a preferable technical scheme, each 2mL of the composition also comprises 0.08mg NGF. The preparation method of the composition is simple, the cell morphology in the composition is not changed, and the cell activity rate can reach 98.4% -99.5%. Has better effect on treating the common disc degeneration of the disc degeneration. In the specific use process, on the premise of not changing the original spinal mechanical structure and not replacing the original intervertebral disc, the function of regenerating the intervertebral disc is generated in situ, TDR is not needed, the risk, sequelae and complications are reduced, the application operation difficulty is low, the acceptable degree of a patient is higher, and the trauma is smaller.
Description
Technical Field
The invention belongs to the technical field of intervertebral disc degeneration diseases, and particularly relates to a PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating intervertebral disc degeneration diseases.
Background
Lower Back Pain (LBP) is an important public health problem. About 6.5 hundred million people in the world are affected by the world, and the social and economic consumption of the people is continuously increasing as the population ages. Furthermore, lower back pain is the second leading cause of hospitalization, and Chris Maher professor 2017 called lower back pain in Lancet is the leading cause of disability in developed and developing countries and loss of healthy life years (Years Lived with Disability).
The conventional treatment modes such as medicines, operations and the like for treating the intervertebral disc-derived lumbago have relatively high treatment cost, relatively high pain and relatively high trauma to patients, and long-term researches show that the diseases also have a certain probability of causing accelerated degeneration of adjacent intervertebral discs. Currently, intervertebral disc-derived lumbago is generally a medication, and if failed, is selected as a final choice by invasive surgery (spinal fusion or disc replacement). The clinical success rate of spinal fusion is between 50% and 70%. Spinal fusion may lead to the development of degeneration of adjacent segments, a condition that often requires re-surgery. Furthermore, spinal fusion is costly and may incur additional costs due to long recovery time and lifetime injuries. As for disc replacement (TDR), meta analysis of a randomized controlled study indicated that TDR had similar safety and efficacy as spinal fusion in a 2 year follow-up study, and that TDR exhibited advantages in improving physiological function, alleviating pain and shortening hospitalization. However, an earlier systematic review indicates that: spinal surgeons should be careful enough when performing a large number of disc replacements because complications may occur in later years.
Given the limitations of these therapeutic regimens, the approach of supplementing the nucleus pulposus with cells and biological materials (cytotherapy) has now become an alternative to preventing disc degeneration, given the recent knowledge of the pathophysiological mechanisms of disc degeneration, in particular the consumption of nucleus pulposus cells during disc degeneration. A number of preclinical studies have been conducted and partially demonstrated the scientificity of this regenerative cell therapy. Meanwhile, the effectiveness of cell therapies has been evaluated in preliminary studies of the human body. But there is no composition for disc degeneration.
Disclosure of Invention
The technical problem to be solved by the invention is that in the prior art, the common TDR for treating disc degeneration is used for treating disc degeneration, but the risk is high, and complications are common, and the present researches mention that the common TDR can be realized by using cells and biological materials to carry out nucleus pulposus supplementation (cell therapy), so that how to prepare the PRP gel-loaded umbilical mesenchymal stem cell composition suitable for treating disc degeneration diseases is the technical problem to be solved.
Therefore, the PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating the intervertebral disc degeneration is researched, and in a specific use process, the PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating the intervertebral disc degeneration generates the function of regenerating the intervertebral disc in situ on the premise of not changing the original spinal mechanical structure and not replacing the original intervertebral disc.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
a PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating an intervertebral disc degeneration disease, comprising at least 5 x 10-5 umbilical cord mesenchymal stem cells per 2mL of the composition, PRP gel and 100 units of thrombin.
Further, 0.08mg NGF is also included per 2mL of the composition.
Further, in the composition, the average cell activity of the umbilical cord mesenchymal stem cells is more than or equal to 98%.
Further, the composition is prepared according to the following steps:
5X 10-5 umbilical cord mesenchymal stem cells were resuspended with 2ml PRP, mixed well, 100 units of thrombin were added thereto, and mixed well.
Further, the composition is prepared according to the following steps:
2ml of PRP was taken, 0.08mg of NGF was added thereto, and mixed well, then 5X 10≡5 umbilical cord mesenchymal stem cells were resuspended in 2ml of PRP to which NGF was added, and 100 units of thrombin was added thereto, and mixed well.
NGF plays a role in nourishing nerve cells, PRP is mainly a repairing effect, and the two are combined to reduce the influence of degenerative diseases on a nerve system.
Further, the method comprises the steps of,
the preparation method of the PRP gel comprises the following steps:
(1) The blood sample is divided into 15ml centrifuge tubes, each tube does not exceed 15ml,300g (increasing speed 9 and decreasing speed 7) is centrifuged for 8min to 10min;
(2) The whole blood is divided into three layers, wherein the upper layer is supernatant, the lower layer is red blood cells, a thin pale yellow interface layer, namely a PRP layer, is visible at the joint of the two layers, a liquid level is contacted by a liquid-transferring gun, the whole supernatant is carefully sucked to 3mm below the interface layer, transferred into a 15ml centrifuge tube, balanced, and centrifuged for 6min at 800g (rising speed 9 and falling speed 7);
(3) The liquid in the centrifuge tube is divided into two layers, 3/4 supernatant is sucked and transferred into another centrifuge tube by a liquid transfer device, the rest serum is contacted with the liquid level by the liquid transfer device, the supernatant is carefully sucked and transferred into a new centrifuge tube by 3mm below the intersection, namely PRP gel.
Further, the method comprises the steps of,
the centrifugation time in step (1) was 8min.
Further, the umbilical cord mesenchymal stem cells are cultured in the following manner:
(1) Horizontally placing the culture flask to ensure that umbilical cord tissue blocks are uniformly distributed on the whole bottom surface as much as possible, and placing the culture flask in a carbon dioxide constant temperature and humidity incubator; culture conditions: 37 ℃ and the volume fraction of carbon dioxide is 5%;
(2) After one week, taking out the culture flask, observing whether stem cells grow or not, observing every day until the stem cells grow, and starting to change the liquid;
(3) Half liquid change: if stem cells are observed to grow in the culture flask, half liquid exchange is carried out, the culture flask is slightly inclined, old culture medium is gently sucked by a pipette (note that tissue blocks are not sucked out), the fresh culture medium with the same amount is complemented, and a carbon dioxide constant temperature and humidity incubator is placed for starting culture, wherein the culture conditions are as follows: observing the growth condition of cells at 37 ℃ with the volume fraction of carbon dioxide of 5%, wherein the fusion degree of the concentrated cells reaches 80% -90%;
(4) Sucking and discarding the culture solution and tissue blocks in the culture flask, and gently flushing the cell culture flask with sodium chloride injection for 1-2 times;
(5) Digestion: digesting the cells until the cells are observed to be mostly deformed into a round shape by the shuttle and shed under an inverted microscope;
(6) Collecting cells, adding 10-15 ml of sodium chloride injection into each original culture flask, gently blowing, and blowing off adherent cells;
(7) And (3) filtering: collecting cell suspension to a 50ml centrifuge tube, and filtering by a screen;
(8) Cell count: gently beating, re-suspending cells, uniformly mixing by beating, sampling and counting;
(9) And (3) centrifugal washing: counting 5 x 10-5, centrifuging and washing, and pouring out the supernatant, wherein the bottom stem cells are umbilical cord mesenchymal stem cells.
The invention has the advantages that:
(1) The PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating the intervertebral disc degeneration disease has a simple preparation method, the cell morphology in the composition is not changed, and the cell activity rate can reach 98.4% -99.5%. Has better effect on treating the common disc degeneration of the disc degeneration.
(2) The PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating the intervertebral disc degeneration disease provided by the invention has the advantages that in a specific use process, the PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating the intervertebral disc degeneration has the advantages that on the premise of not changing the original spinal mechanical structure and not replacing the original intervertebral disc, the effect of regenerating the intervertebral disc is generated in situ, TDR (time domain reflectometer) is not needed, the risk and sequelae and complications are reduced, the application operation difficulty is low, the patient acceptability is higher, and the wound is smaller.
Drawings
FIG. 1 is a graph showing two key indexes of nucleus pulposus cells col2 and sox-9 after the PRP gel loaded with umbilical cord mesenchymal stem cells, the PRP gel without umbilical cord mesenchymal stem cells and normal saline are respectively injected in clinic.
Detailed Description
The invention is further illustrated by the following specific examples, which should be understood to those skilled in the art that variations and modifications can be made without departing from the principles of the invention, and these should also be considered to be within the scope of the invention.
A PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating an intervertebral disc degeneration disease, comprising at least 5 x 10-5 umbilical cord mesenchymal stem cells per 2mL of the composition, PRP gel and 100 units of thrombin.
In some embodiments, 0.08mg NGF is also included per 2mL of the composition.
In some embodiments, the composition has an average cell activity of umbilical cord mesenchymal stem cells of greater than or equal to 98%.
In some embodiments, the composition is made according to the following steps:
5X 10-5 umbilical cord mesenchymal stem cells were resuspended with 2ml PRP, mixed well, 100 units of thrombin were added thereto, and mixed well.
The composition is prepared according to the following steps:
2ml of PRP was taken, 0.08mg of NGF was added thereto, and mixed well, then 5X 10≡5 umbilical cord mesenchymal stem cells were resuspended in 2ml of PRP to which NGF was added, and 100 units of thrombin was added thereto, and mixed well.
The preparation method of the PRP gel comprises the following steps:
(1) After the injector plug is slightly loosened, the tube cover is pulled out, the blood sample is averagely split into 15ml centrifuge tubes, each tube does not exceed 15ml,300g (speed-up 9, speed-down 7) is centrifuged for 8min to 10min;
(2) The whole blood is divided into three layers, wherein the upper layer is supernatant, the lower layer is red blood cells, a thin pale yellow interface layer, namely a PRP layer, is visible at the joint of the two layers, a liquid level is contacted by a liquid-transferring gun, the whole supernatant is carefully sucked to 3mm below the interface layer, transferred into a 15ml centrifuge tube, balanced, and centrifuged for 6min at 800g (rising speed 9 and falling speed 7);
(3) The liquid in the centrifuge tube is divided into two layers, 3/4 supernatant is sucked and transferred into another centrifuge tube by a liquid transfer device, the rest serum is contacted with the liquid level by the liquid transfer device, the supernatant is carefully sucked and transferred into a new centrifuge tube by 3mm below the intersection, namely PRP gel.
In some embodiments, the centrifugation time in step (1) is 8min.
The umbilical cord mesenchymal stem cells are cultured in the following manner (in the following steps, the culture medium is the commercially available Dayou stem cell culture medium):
(1) Horizontally placing the culture flask to ensure that umbilical cord tissue blocks are uniformly distributed on the whole bottom surface as much as possible, and placing the culture flask in a carbon dioxide constant temperature and humidity incubator; culture conditions: 37 ℃ and the volume fraction of carbon dioxide is 5%;
(2) After one week, taking out the culture flask, observing whether stem cells grow or not, observing every day until the stem cells grow, and starting to change the liquid;
(3) Half liquid change: if stem cells are observed to grow in the culture flask, half liquid exchange is carried out, the culture flask is slightly inclined, old culture medium is gently sucked by a pipette (note that tissue blocks are not sucked out), the fresh culture medium with the same amount is complemented, and a carbon dioxide constant temperature and humidity incubator is placed for starting culture, wherein the culture conditions are as follows: observing the growth condition of cells at 37 ℃ with the volume fraction of carbon dioxide of 5%, wherein the fusion degree of the concentrated cells reaches 80% -90%;
(4) Sucking and discarding the culture solution and tissue blocks in the culture flask, and gently flushing the cell culture flask with sodium chloride injection for 1-2 times;
(5) Digestion: digesting the cells until the cells are observed to be mostly deformed into a round shape by the shuttle and shed under an inverted microscope;
(6) Collecting cells, adding 10-15 ml of sodium chloride injection into each original culture flask, gently blowing, and blowing off adherent cells;
(7) And (3) filtering: collecting cell suspension to a 50ml centrifuge tube, and filtering by a screen;
(8) Cell count: gently beating, re-suspending cells, uniformly mixing by beating, sampling and counting;
(9) And (3) centrifugal washing: counting 5 x 10-5, centrifuging and washing, and pouring out the supernatant, wherein the bottom stem cells are umbilical cord mesenchymal stem cells.
Example 1:
a PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating an intervertebral disc degeneration disease, comprising at least 5 x 10-5 umbilical cord mesenchymal stem cells per 2mL of the composition, PRP gel and 100 units of thrombin; in the composition, the average cell activity of the umbilical cord mesenchymal stem cells is more than or equal to 98 percent.
The composition is prepared according to the following steps:
5X 10-5 umbilical cord mesenchymal stem cells were resuspended with 2ml PRP gel, mixed well, 100 units of thrombin were added thereto, and mixed well.
The preparation method of the PRP gel comprises the following steps:
(1) After the injector plug is slightly loosened, the tube cover is pulled out, the blood sample is averagely split into 15ml centrifuge tubes, and each tube is centrifuged for 8min with the speed of no more than 15ml and 300g (speed of 9 and speed of 7);
(2) The whole blood is divided into three layers, wherein the upper layer is supernatant, the lower layer is red blood cells, a thin pale yellow interface layer, namely a PRP layer, is visible at the joint of the two layers, a liquid level is contacted by a liquid-transferring gun, the whole supernatant is carefully sucked to 3mm below the interface layer, transferred into a 15ml centrifuge tube, balanced, and centrifuged for 6min at 800g (rising speed 9 and falling speed 7);
(3) The liquid in the centrifuge tube is divided into two layers, 3/4 supernatant is sucked and transferred into another centrifuge tube by a liquid transfer device, the rest serum is contacted with the liquid level by the liquid transfer device, the supernatant is carefully sucked and transferred into a new centrifuge tube by 3mm below the intersection, namely PRP gel.
The umbilical cord mesenchymal stem cells are cultured in the following manner (in the following steps, the culture medium is the commercially available Dayou stem cell culture medium):
(1) Horizontally placing the culture flask to ensure that umbilical cord tissue blocks are uniformly distributed on the whole bottom surface as much as possible, and placing the culture flask in a carbon dioxide constant temperature and humidity incubator; culture conditions: 37 ℃ and the volume fraction of carbon dioxide is 5%;
(2) After one week, taking out the culture flask, observing whether stem cells grow or not, observing every day until the stem cells grow, and starting to change the liquid;
(3) Half liquid change: if stem cells are observed to grow in the culture flask, half liquid exchange is carried out, the culture flask is slightly inclined, old culture medium is gently sucked by a pipette (note that tissue blocks are not sucked out), the fresh culture medium with the same amount is complemented, and a carbon dioxide constant temperature and humidity incubator is placed for starting culture, wherein the culture conditions are as follows: observing the growth condition of cells at 37 ℃ with the volume fraction of carbon dioxide of 5%, wherein the fusion degree of the concentrated cells reaches 80% -90%;
(4) Sucking and discarding the culture solution and tissue blocks in the culture flask, and gently flushing the cell culture flask with sodium chloride injection for 1-2 times;
(5) Digestion: digesting the cells until the cells are observed to be mostly deformed into a round shape by the shuttle and shed under an inverted microscope;
(6) Collecting cells, adding 10-15 ml of sodium chloride injection into each original culture flask, gently blowing, and blowing off adherent cells;
(7) And (3) filtering: collecting cell suspension to a 50ml centrifuge tube, and filtering by a screen;
(8) Cell count: gently beating, re-suspending cells, uniformly mixing by beating, sampling and counting;
(9) And (3) centrifugal washing: counting 5 x 10-5, centrifuging and washing, and pouring out the supernatant, wherein the bottom stem cells are umbilical cord mesenchymal stem cells.
The PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating the intervertebral disc degeneration disease obtained in the above example 1 was detected, and the detection result was shown in the following table 1, the cell morphology was not changed, and the cell viability rate was 98.4% -99.3%.
TABLE 1 results of cell detection for the composition of example 1
| Number of times | CD105+(％) | CD73+(％) | CD90+(％) | CD45+(％) | CD34+(％) | HLA-DR(％) | Cell viability (%) |
| First time | 100％ | 99.4 | 99.9 | 0.01 | 0.07 | 0.04 | 99.1 |
| Second time | 99.6 | 99.8 | 99.1 | 0.04 | 0.56 | 0.07 | 98.4 |
| Third time | 99.5 | 99.6 | 99.4 | 0.08 | 0.27 | 0.89 | 99.3 |
| Fourth time | 99.2 | 99.7 | 99.7 | 0.24 | 0.68 | 0.21 | 99.2 |
| Fifth time | 99.1 | 99.4 | 99.6 | 0.81 | 0.09 | 0.31 | 98.5 |
| Sixth time | 99.5 | 99.8 | 100 | 0.36 | 0.06 | 0.03 | 98.8 |
Example 2:
a PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating an intervertebral disc degeneration disease, comprising at least 5×10ζ5 umbilical cord mesenchymal stem cells per 2mL of the composition, PRP gel, 0.08mg NGF and 100 units of thrombin.
The composition is prepared according to the following steps:
2ml of PRP was taken, 0.08mg of NGF was added thereto, and mixed well, then 5X 10≡5 umbilical cord mesenchymal stem cells were resuspended in 2ml of PRP to which NGF was added, and 100 units of thrombin was added thereto, and mixed well.
Wherein, the PRP gel was prepared in the same manner as in example 1.
The umbilical cord mesenchymal stem cells were cultured in the same manner as in example 1.
TABLE 2 results of cell detection for the composition of example 2
| Number of times | CD105+(％) | CD73+(％) | CD90+(％) | CD45+(％) | CD34+(％) | HLA-DR(％) | Cell viability (%) |
| First time | 99.4％ | 99.5 | 100 | 0.02 | 0.13 | 0.65 | 99.3 |
| Second time | 99.6 | 99.6 | 99.4 | 0.12 | 0.33 | 0.27 | 99.1 |
| Third time | 99.7 | 99.4 | 99.8 | 0.04 | 0.08 | 0.31 | 98.7 |
| Fourth time | 99.6 | 99.7 | 99.6 | 0.02 | 0.08 | 0.08 | 98.8 |
| Fifth time | 100 | 99.8 | 99.5 | 0.13 | 0.21 | 0.12 | 99.5 |
| Sixth time | 99.3 | 99.6 | 99.8 | 0.24 | 0.37 | 0.52 | 99.2 |
Application example 1
The PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating the intervertebral disc degeneration disease obtained in the above example 1 is respectively used for treating a clinical intervertebral disc degeneration patient, a clinical patient with lumbar disc herniation, a clinical patient with a subvertebroscopic nuclectomy, and a clinical patient with lumbar pain caused by lumbar disc degeneration by an intervertebral foramen mirror injection method.
Application example 2
The PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating the intervertebral disc degeneration disease obtained in the above example 2 is respectively used for treating a clinical intervertebral disc degeneration patient, a clinical patient with lumbar disc herniation, a clinical patient with a subvertebroscopic nuclectomy, and a clinical patient with lumbar pain caused by lumbar disc degeneration by an intervertebral foramen mirror injection method.
Comparative example 1 was used
The PRP gel without the umbilical cord mesenchymal stem cells is respectively used for treating clinical patients suffering from intervertebral disc degeneration, clinical patients with lumbar disc herniation imitating the operation of nuclectomy under the intervertebral foramen mirror and patients suffering from lumbar vertebra pain caused by lumbar vertebra degeneration in a clinical mode through an intervertebral foramen mirror injection mode.
Comparative example 2 was used
Physiological saline is respectively used for treating clinical patients suffering from intervertebral disc degeneration, clinical patients with lumbar disc herniation, which are subjected to the operation of performing the nuclectomy under the intervertebral foramen mirror, and clinical patients suffering from lumbar vertebra pain caused by lumbar vertebra degeneration in an injection mode of the intervertebral foramen mirror.
The specific results are shown in Table 3 below:
table 3: the results of the above application examples 1-2 and comparative examples 1-2
| Numbering device | Disc height | Intervertebral disc water content | VAS scoring |
| Application example 1 | +9％ | +11％ | 7 min to 4 min |
| Application example 2 | +10％ | +11.5％ | 7 min to 3 min |
| Comparative example 1 was used | +1％ | +3％ | Unchanged |
| Comparative example 2 was used | Unchanged | Unchanged | Unchanged |
FIG. 1 shows two key indexes of nucleus pulposus cell col2 and sox-9 after PRP gel is respectively injected into the PRP gel loaded umbilical cord mesenchymal stem cells, the PRP gel not loaded umbilical cord mesenchymal stem cells and normal saline, and the relative density of the nucleus pulposus cells of the umbilical cord mesenchymal stem cells is increased by the PRP gel, so that the effect of the application example 1 is superior to that of other comparative examples 1 and 2.
The foregoing is merely a preferred embodiment of the present invention and is not limited thereto. Other variations or modifications of the above description will be apparent to those of skill in the art. It is not necessary or nor practical to exemplify all embodiments herein. While obvious variations or modifications of the solution are still within the scope of the invention.
Claims (2)
1. A PRP gel-loaded umbilical cord mesenchymal stem cell composition for use in the treatment of an intervertebral disc degeneration disease, characterized in that at least 5 x 10-5 PRP gel, 100 units of thrombin and 0.08mg NGF are included per 2mL of the composition; in the composition, the average cell activity of umbilical cord mesenchymal stem cells is more than or equal to 98%;
the preparation method of the PRP gel comprises the following steps:
(1) The blood sample is divided into 15ml centrifuge tubes in average, each tube is not more than 15ml,300g is centrifuged for 8-10 min, the speed is increased by 9, and the speed is reduced by 7;
(2) The whole blood is divided into three layers, wherein the upper layer is supernatant, the lower layer is red blood cells, a thin pale yellow interface layer, namely a PRP layer, is visible at the joint of the two layers, a liquid level is contacted by a liquid-transferring gun, the whole supernatant is carefully sucked to 3mm below the interface layer, and is transferred into a 15ml centrifuge tube for balancing, and 800g is centrifuged for 6min, and the speed is increased by 9 and reduced by 7;
(3) The liquid in the centrifuge tube is divided into two layers, 3/4 supernatant is sucked and transferred into another centrifuge tube by a liquid transfer device, the rest serum is contacted with the liquid level by the liquid transfer device, the supernatant is carefully sucked and transferred into a new centrifuge tube by 3mm below the intersection, namely PRP gel.
2. The PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating an intervertebral disc degeneration disease of claim 1, wherein,
the umbilical cord mesenchymal stem cells are cultured in the following manner:
(1) Horizontally placing the culture flask to ensure that umbilical cord tissue blocks are uniformly distributed on the whole bottom surface as much as possible, and placing the culture flask in a carbon dioxide constant temperature and humidity incubator; culture conditions: 37 ℃ and the volume fraction of carbon dioxide is 5%;
(2) After one week, taking out the culture flask, observing whether stem cells grow or not, observing every day until the stem cells grow, and starting to change the liquid;
(3) Half liquid change: if stem cells are observed to grow in the culture flask, half liquid exchange is carried out, the culture flask is slightly inclined, the old culture medium is gently sucked by a pipette, tissue blocks are not required to be sucked out, the fresh culture medium with the same amount is complemented, and a carbon dioxide constant temperature and humidity incubator is placed for starting culture under the conditions of: observing the growth condition of cells at 37 ℃ with the volume fraction of carbon dioxide of 5%, wherein the fusion degree of the concentrated cells reaches 80% -90%;
(4) Sucking and discarding the culture solution and tissue blocks in the culture flask, and gently flushing the cell culture flask with sodium chloride injection for 1-2 times;
(5) Digestion: digesting the cells until the cells are observed to be mostly deformed into a round shape by the shuttle and shed under an inverted microscope;
(6) Collecting cells, adding 10-15 ml of sodium chloride injection into each original culture bottle, gently blowing, and blowing off adherent cells;
(7) And (3) filtering: collecting cell suspension to a 50ml centrifuge tube, and filtering by a screen;
(8) Cell count: gently beating, re-suspending cells, uniformly mixing by beating, sampling and counting;
(9) And (3) centrifugal washing: counting 5 x 10-5, centrifuging and washing, and pouring out the supernatant, wherein the bottom stem cells are umbilical cord mesenchymal stem cells.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011151536 | 2020-10-26 | ||
| CN2020111515365 | 2020-10-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112402365A CN112402365A (en) | 2021-02-26 |
| CN112402365B true CN112402365B (en) | 2023-10-03 |
Family
ID=74828016
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011217356.2A Active CN112402365B (en) | 2020-10-26 | 2020-11-04 | PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating intervertebral disc degeneration diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112402365B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113425672A (en) * | 2021-07-05 | 2021-09-24 | 福建华民生物科技有限公司 | Double-layer medicine for treating protrusion of lumbar intervertebral disc |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113631173A (en) * | 2019-01-02 | 2021-11-09 | 迈索布拉斯特国际有限公司 | Method for treating lumbago |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012092458A2 (en) * | 2010-12-30 | 2012-07-05 | Anthrogenesis Corporation | Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof |
-
2020
- 2020-11-04 CN CN202011217356.2A patent/CN112402365B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113631173A (en) * | 2019-01-02 | 2021-11-09 | 迈索布拉斯特国际有限公司 | Method for treating lumbago |
Non-Patent Citations (5)
| Title |
|---|
| 人脐带间充质干细胞移植修复兔退变椎间盘的初步研究;王彦强 等;《中国骨与关节外科》;20200709;第523-526页 * |
| 富含血小板血浆凝胶复合脂肪间充质干细胞构建可注射组织工程髓核";马健 等;《中国脊柱脊髓杂志》;20111231;第353-367页 * |
| 郝岱峰 等.使用方法.《创面修复外科住院医师手册》.2015, * |
| 非接触式共培养体系对脐带间充质干细胞向类髓核细胞的诱导分化效应;张燕等;《脊柱外科杂志》;20110828(第04期);全文 * |
| 高洪宽.临床骨科手术技巧与康复.《临床骨科手术技巧与康复》.2018,第171页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112402365A (en) | 2021-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Loibl et al. | Controversies in regenerative medicine: Should intervertebral disc degeneration be treated with mesenchymal stem cells? | |
| Hendrich et al. | Safety of autologous bone marrow aspiration concentrate transplantation: initial experiences in 101 patients | |
| US20160235890A1 (en) | Intervertebral disc repair, methods and devices therefor | |
| CN104958320A (en) | Cell preparation for treating osteoarthritis and preparation method thereof | |
| CN108865986B (en) | Mesenchymal stem cell preparation for repairing articular cartilage damage/defect and preparation method and application thereof | |
| CN111849882A (en) | Mesenchymal stem cell exosome and preparation method and application thereof | |
| Karina et al. | Safety of technique and procedure of stromal vascular fraction therapy: from liposuction to cell administration | |
| Hee et al. | Effects of implantation of bone marrow mesenchymal stem cells, disc distraction and combined therapy on reversing degeneration of the intervertebral disc | |
| CN106421920B (en) | A kind of fat filler and preparation method thereof | |
| CN105970300A (en) | Method for establishing human umbilical cord mesenchymal stem cell bank by adopting blood serum substituent | |
| Xu et al. | Histological observation of a gelatin sponge transplant loaded with bone marrow-derived mesenchymal stem cells combined with platelet-rich plasma in repairing an annulus defect | |
| CN112294845A (en) | Synovial mesenchymal stem cell combined PRP preparation for repairing articular cartilage damage and preparation method and application thereof | |
| CN112402365B (en) | PRP gel-loaded umbilical cord mesenchymal stem cell composition for treating intervertebral disc degeneration diseases | |
| CN111973632B (en) | Stem cell preparation for treating diabetes and preparation method thereof | |
| Tiryaki et al. | Hybrid stromal vascular fraction (Hybrid-SVF): A new paradigm in mechanical regenerative cell processing | |
| CN111297901B (en) | Preparation method and application of autologous fat glue and mesenchymal stem cells derived from autologous fat glue | |
| Rhim et al. | Mesenchymal stem cells for enhancing biological healing after meniscal injuries | |
| CN109517786B (en) | Pluripotent stem cell preparation with repairing function and application thereof | |
| CN110935010A (en) | A kind of stem cell preparation and growth factor composition and its preparation method and application | |
| Zuo et al. | Utilizing tissue‐engineered cartilage or BMNC‐PLGA composites to fill empty spaces during autologous osteochondral mosaicplasty in porcine knees | |
| CN110339212A (en) | Mescenchymal stem cell preparation and its preparation method and application | |
| Mizuno et al. | Biological therapeutic modalities for intervertebral Disc diseases: an orthoregeneration network (ON) foundation review | |
| CN111235091A (en) | Extraction reagent and extraction method for human autologous fat vascular stroma component SVF | |
| CN115381856A (en) | Use of adipose-derived mesenchymal stem cells in the preparation of drugs or preparations for treating knee osteoarthritis | |
| US20110142793A1 (en) | Composition for treating articular cartilage defect, and method of manufacture thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |